| Trial ID: | L2019 |
| Source ID: | NCT01542060
|
| Associated Drug: |
Biphasic Insulin Aspart 30
|
| Title: |
Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: biphasic insulin aspart 30
|
| Outcome Measures: |
Primary: HbA1c (glycosylated haemoglobin) | Secondary: FBG (Fasting Blood Glucose)|Quality of life assessed through the WHO-DTSQ (World Health Organization-Diabetes Treatment Satisfaction Questionnaire)|Incidence of adverse events|Incidence of hypoglycaemic episodes
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
298
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2004-01
|
| Completion Date: |
2004-12
|
| Results First Posted: |
|
| Last Update Posted: |
2012-04-12
|
| Locations: |
Amman, 11844, Jordan
|
| URL: |
https://clinicaltrials.gov/show/NCT01542060
|
